Effects of Mipragoside® on Ocular Allergic Inflammation in the Rabbit

We evaluated the pharmacodynamic and pharmacokinetic profile of MipragosideR, a monosialoganglioside isopropyl-ester (as 0.57% w/w ophthalmic gel), on allergic inflammation of the eye induced by reverse passive Arthus reaction, on a non-immune mast cell degranulation elicited by compound 48/80 and on ocular inflammation produced by horse serum. Conjunctiva was sensitized by injection of rabbit antisera to bovine proteins and the allergic conjunctivitis was triggered by intravenous administration of bovine gamma globulin. The permeability of the blood-conjunctival barrier was evaluated by a fluorometric method. Compound 48/80 was topically administered at concentration of 50mg/ml and histological analysis of conjunctiva was performed. Horse serum was administered by intravenous injection at different days. The pharmacokinetic profile of topical 3H-Mipragoside® on 48/80 model was investigated and compared with untreated animals. Mipragoside® treatment significantly reduced (p<0.05 vs placebo) the conjunctival vasopermeability induced by reverse passive Arthus reaction as well as successfully reduced the eosinophil levels in the conjunctival epithelium (p<0.01 vs placebo) elicited by compound 48/80. Further, Mipragoside® successfully reduced the primary signs of ocular inflammation produced by horse serum administration. A radiotracer technique was used to evaluate the disposition of 3H-Mipragoside® in the rabbit ocular tissues. Disposition of the drug was monitored at 30, 60, 120 and 240 min. 3H-Mipragoside® levels in the inflamed conjunctiva were significantly higher (p<0.01) than in the control eye. © 1993, Mary Ann Liebert, Inc. All rights reserved.